PHATHOM PHARMACEUTICALS, INC. Earnings Per Share, Basic and Diluted
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Earnings Per Share, Basic and Diluted of -$1.07 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.07.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.95.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.98.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.00.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2021 was -$3.89.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.88.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2019 was -$22.45.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2018 was -$0.21.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$1.07 10-Q · filed 2022-05-10 | -$2.02 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$3.00 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$4.00 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.93 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.93 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.89 10-K · filed 2022-03-01 |
| 2021-09-30 | -$0.98 10-Q · filed 2021-11-08 | -$1.98 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$2.94 10-Q · filed 2021-11-08 | -$4.48 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2021-06-30 | -$1.00 10-Q · filed 2021-08-10 | -$1.96 10-Q · filed 2021-08-10 | -$3.51 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$4.54 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2021-03-31 | -$0.96 10-Q · filed 2022-05-10 | -$2.52 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$3.55 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$4.21 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2020-12-31 | -$1.58 10-K · filed 2021-03-30 | -$2.61 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$3.25 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$3.88 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.02 10-Q · filed 2021-11-08 | -$1.66 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.29 10-Q · filed 2021-11-08 | -$5.61 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2020-06-30 | -$0.64 10-Q · filed 2021-08-10 | -$1.26 10-Q · filed 2021-08-10 | -$4.63 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$8.51 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2020-03-31 | -$0.62 10-Q · filed 2021-05-11 | -$4.13 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$8.66 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$15.39 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2019-12-31 | -$3.97 10-K · filed 2021-03-30 | -$10.37 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$19.67 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$22.45 10-K · filed 2021-03-30 |
| 2019-09-30 | -$9.30 10-K · filed 2021-03-30 | -$22.23 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$22.87 10-Q · filed 2020-11-10 | -$23.04 derived: net income ÷ weighted average shares · filed 2021-03-30 |
| 2019-06-30 | -$13.11 10-K · filed 2021-03-30 | -$13.40 10-Q · filed 2020-08-06 | -$13.40 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$13.40 derived: net income ÷ weighted average shares · filed 2021-03-30 |
| 2019-03-31 | -$0.19 10-K · filed 2021-03-30 | -$0.26 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$0.30 derived: net income ÷ weighted average shares · filed 2021-03-30 | -$0.34 derived: net income ÷ weighted average shares · filed 2021-03-30 |
| 2018-12-31 | -$0.07 10-K · filed 2020-03-19 | -$0.11 derived: net income ÷ weighted average shares · filed 2020-03-19 | -$0.15 derived: net income ÷ weighted average shares · filed 2020-03-19 | -$0.21 10-K · filed 2020-03-19 |
| 2018-09-30 | -$0.04 10-K · filed 2020-03-19 | -$0.08 derived: net income ÷ weighted average shares · filed 2020-03-19 | -$0.14 10-Q · filed 2019-11-25 | |
| 2018-06-30 | -$0.04 10-K · filed 2020-03-19 | -$0.10 derived: net income ÷ weighted average shares · filed 2020-03-19 | ||
| 2018-03-31 | -$0.07 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |